Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,279 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MRI Study Clear all
Completed Phase 2 Interventional

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

NCT05064319
View directory record Official record
Conditions
Bipolar Disorder, Cannabis Use, Schizoaffective Disorder, Bipolar Type, Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

NCT06865677
View directory record Official record
Conditions
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
Interventions
Sacituzumab Govitecan, EKG, Brain MRI, CT scans, Tumor biopsy, Loperamide, Octreotide, Diphenoxylate/Atropine, Antiemetics
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

Baby Brain Recovery Study

NCT05013736
View directory record Official record
Conditions
Perinatal Stroke
Interventions
Magnetic Resonance Imaging, Behavioral Assessments, Non invasive Transcranial Magnetic Stimulation
Device · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
0 Years to 24 Months
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

NCT03341806
View directory record Official record
Conditions
Glioblastoma, GBM
Interventions
Avelumab, MRI-guided LITT therapy
Drug · Combination Product
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 23, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

NCT03123744
View directory record Official record
Conditions
Cancer, Advanced
Interventions
Palbociclib 125mg
Drug
Lead sponsor
Razelle Kurzrock, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 23, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional

Terazosin and Parkinson's Disease Extension Study

NCT05109364
View directory record Official record
Conditions
Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease
Interventions
Terazosin therapy
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 1 Interventional

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

NCT07217028
View directory record Official record
Conditions
SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed No phase listed Observational

Noninvasive Imaging of Heart Failure: A Pilot Study

NCT01160471
View directory record Official record
Conditions
MRI, Acquired Heart Disease, Myocardial Fibrosis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

NCT07518784
View directory record Official record
Conditions
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
LiverScope® exam, MR exam, Blood draw, Body measurements, Questionnaire
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

MRg-NIRS Imaging System Breast Cancer Trial

NCT06400563
View directory record Official record
Conditions
Breast Cancer
Interventions
MRg-NIRS
Device
Lead sponsor
Keith D. Paulsen
Other
Eligibility
18 Years to 83 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

NCT01767792
View directory record Official record
Conditions
Neurofibromatosis Type 2, Progressive Vestibular Schwannomas
Interventions
Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 23, 2026, 10:45 AM EDT
Terminated Not applicable Interventional Results available

Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors

NCT00630292
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic Resonance Angiography (MRA) of the Breast
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2010 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 2Phase 3 Interventional

Risk Reduction for Alzheimer's Disease

NCT02913664
View directory record Official record
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions
Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise
Drug · Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 23, 2026, 10:45 AM EDT
Terminated Not applicable Interventional

Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer

NCT01613521
View directory record Official record
Conditions
Cervical Cancer
Interventions
DCE-MRI and 18F-FMISO PET
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 23, 2026, 10:45 AM EDT
Active, not recruiting No phase listed Observational

LTFU Study of Subjects Who Received GRNOPC1

NCT05919563
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Magnetic Resonance Imaging (MRI)
Diagnostic Test
Lead sponsor
Lineage Cell Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
3
States / cities
Palo Alto, California • Atlanta, Georgia • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 23, 2026, 10:45 AM EDT
Withdrawn No phase listed Observational

Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection

NCT00811863
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis, Renal Insufficiency
Interventions
Not listed
Lead sponsor
Guerbet
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

NCT02410200
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 23, 2026, 10:45 AM EDT
Completed No phase listed Observational

The Impact of Exercise-Induced Cardiac Remodeling on Myocardial Efficiency

NCT04580693
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
PET Scan
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

THC Memory & Reward Learning Pilot

NCT05116527
View directory record Official record
Conditions
Marijuana, THC, Cannabis
Interventions
Marijuana, Hash, THC, or Grass, Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

NCT06330805
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
Procedure · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Early Phase 1 Interventional Results available

Neuroendocrine Risk for PTSD in Women

NCT03973229
View directory record Official record
Conditions
PTSD, Trauma
Interventions
Estradiol patch, Placebo patch
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Brain Biomarkers of Response to Treatment for Apraxia of Speech

NCT02046941
View directory record Official record
Conditions
Aphasia, Stroke
Interventions
Speech Production Treatment
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants

NCT04903288
View directory record Official record
Conditions
AADC Deficiency
Interventions
Eladocagene Exuparvovec
Genetic
Lead sponsor
PTC Therapeutics
Industry
Eligibility
1 Year to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Boston, Massachusetts • Durham, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 10:45 AM EDT